Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Phase 3 Trial Comparing 3-weekly Docetaxel 75 mg/m2 (in a 3 Week Cycle) Versus 2-weekly Docetaxel 50 mg/m2 (in a 4 Week Cycle) in Combination With Darolutamide + ADT in Patients With mHSPC

NCT05676203 is registered in ClinicalTrials.gov with Jena University Hospital as lead sponsor.

NCT NCT05676203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05676203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Phase 3 Trial Comparing 3-weekly Docetaxel 75 mg/m2 (in a 3 Week Cycle) Versus 2-weekly Docetaxel 50 mg/m2 (in a 4 Week Cycle) in Combination With Darolutamide + ADT in Patients With mHSPC
Lead sponsor
Jena University Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 16, 2023
Completion date
December 31, 2026
Enrollment
250 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer (mhspc)